ArticleExperimental hematology & oncology2024

The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling.

Alexander R Marr et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.